Assertio (US:ASRT) ZACKS·2025-08-11 23:56Company Performance - Assertio reported a quarterly loss of $0.17 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.10, and compared to a loss of $0.04 per share a year ago, indicating a significant decline in performance [1] - The company posted revenues of $29.22 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 4.55%, but down from $31.13 million in the same quarter last year [2] - Over the last four quarters, Assertio has surpassed consensus EPS estimates only once and has topped consensus revenue estimates two times [2] Stock Movement and Outlook - Assertio shares have declined approximately 16.3% since the beginning of the year, contrasting with the S&P 500's gain of 8.6% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the upcoming quarter is -$0.02 on revenues of $31.2 million, and for the current fiscal year, it is -$0.27 on revenues of $117.81 million [7] Industry Context - The Medical - Drugs industry, to which Assertio belongs, is currently ranked in the top 35% of over 250 Zacks industries, suggesting a favorable environment for stocks in this sector [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5] - The estimate revisions trend for Assertio was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6]